Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Negotiating lower drug prices in America: The tradeoffs are worth it.

Konye Ori
Policy
December 10, 2019
516 Shares
Share
Tweet
Share

Negotiating lower drug prices in America could possibly stifle pharmacological innovation. But it would reduce health care cost for most Americans — and that should be all that matters.

If the United States began to regulate drug prices, medications would become cheaper, and Americans would have more access to drugs with lower health care costs. If bills like S.99 – Medicare Drug Price Negotiation Act (MDPNA) ever passes, it would permit the Secretary of Health and Human Services to negotiate lower prices for drugs under Medicare Part D directly with drug manufacturers.

However, some thought-leaders argue that with bills such as MDPNA, we could expect a decline in research and development of new drugs. The judgment is that lowering drug profits would make pharmaceuticals a less desirable industry for investors. And less investment in drugs would mean less research toward new and innovative cures. True to form investors, respond to economic incentives. When they see a market that will pay lots of money for their products, they’ll put more money toward developing the type of drugs that the market wants.

Why support MDPNA or similar efforts if it will inadvertently lead to fewer dollars spent on pharmaceutical research — and less progress developing new drugs for Americans and everybody else? Why support bills like MDPNA if it might lead to fewer biotech firms starting up, or fewer companies deciding to bring a new drug to market?

While investors respond to economic incentives, drug researchers to funds, and drug manufacturers to profits, the health care market is too large and health care too consequential for investors, researchers, and manufacturers to walk away because prices are regulated.

Optimistic? Perhaps. Worth experimenting? Absolutely.

Negotiating lower drug prices will significantly reduce health care costs, and if that means we trade off some level of innovative pharmaceutical advancements, then so be it. The moral imperative to address America’s health care system can no longer be secondary to free-market forces. A little intervention, like negotiating lower drug prices, is due. Perhaps, overdue.

Right now, America’s high drug prices mean that investing in pharmaceuticals can generate significant profits — and that drugs can be too expensive for Americans to afford. As a society, we can no longer accept this. We must make medication more financially accessible to those who need them.

According to Knowledge Ecology International, the price for the cancer drug Avastin is $500 in the United Kingdom, $1500 in Spain, but $4000 in the United States. The price for the hepatitis C drug Harvoni is $17,000 in Switzerland, $25,000 in the United Kingdom, but $35,000 in the United States. The price for arthritis, plaque psoriasis, ankylosing spondylitis, Crohn’s disease, and ulcerative colitis drug Humira is $1362 in the United Kingdom, $822 in Switzerland, but it cost $2,669 in the United States. These drugs are the exact same drugs, whether it’s sold in the United States, in Switzerland, or anywhere else, yet we pay twice and sometimes three times as much as other nations pay for it.

As Sarah Kliff asserts in her Vox article, Americans aren’t buying more drugs than the rest of the world. We’re just spending more on the ones we do buy. And for what? A lucrative market for investors, drug manufacturers, and pharmacological researchers?

The United States continues to subsidize the rest of the world’s drug research by paying out really high prices. Are we, as a country, still willing to pay higher drug prices to get more pharmacological innovation? What good is drug innovation if most Americans are priced out of it?

Other nations proactively regulate and negotiate the prices of new prescription drugs when they come on the market. These nations task a government agency to meet with pharmaceutical companies to evaluate the new drug and negotiate the prices down to an appropriate amount. But in the United States, drugmakers can set their own prices; every safe drug can come on the marketplace even when the drug offers little or no additional benefit. One of several examples is Zaltrap. The metastatic colorectal cancer drug was allowed into the American market, costing about $ 11,000 for a 28 milliliters dosage even though a survey of doctors revealed the drug offered no additional benefit.

When we fail to evaluate drugs for added benefit and negotiate lower prices, Americans are left to bear the brunt through high copays at the drugstore and are not able to afford the life-saving medication they need.

There are thousands of health insurance plans across the country, each with little bargaining power, negotiating its own prices with drugmakers. With bills like MDPNA, the United States will have a government panel that negotiates lower drug prices on behalf of the country’s 319-plus million residents. It would likely be able to demand discounts like those of some European countries. This would mean that health insurance premiums would go down.

But until bills like MDPNA pass, drug makers know that if their products are safe, Medicare will buy them, and they can continue to count on America to make up the price difference in other countries.

Konye Ori is deputy director, Substance Misuse and Mental Health Administration, Indiana University School of Public Health, Bloomington, IN.

Image credit: Shutterstock.com

Prev

The climbing rates of maternal mortality in Black women

December 9, 2019 Kevin 2
…
Next

Is there a link between readmission and a hospital's non-profit status?

December 10, 2019 Kevin 3
…

Tagged as: Public Health & Policy

Post navigation

< Previous Post
The climbing rates of maternal mortality in Black women
Next Post >
Is there a link between readmission and a hospital's non-profit status?

Related Posts

  • Why is the government so scared of directly negotiating drug prices?

    Robert Laszewski
  • Beyond the EpiPen: Irrational drug prices are now pervasive

    Stephen C. Schimpff, MD
  • How hospitals can impact generic drug companies

    Mark Kelley, MD
  • A drug problem in rural Georgia

    Ashish Advani, PharmD
  • Drug ads are a campaign against physician trust

    Judy Salz, MD
  • Crippling drug costs: the role of insurers

    Janice Boughton, MD

More in Policy

  • Unveiling the intricate link between housing costs and health care

    Harvey Castro, MD, MBA
  • Uncovering the truth about racial health inequities in America: a book review

    John Paul Mikhaiel, MD
  • Why affirmative action is crucial for health equity and social justice in medicine

    Katrina Gipson, MD, MPH
  • The untold story of Hispanic/Latino health: Why subgroup data matters

    Matthew B. Alonso
  • Unmasking the brutal reality of gun violence in America: a call to action for unity and meaningful change

    Osmund Agbo, MD
  • Family physicians unite at the U.S. Capitol, seeking congressional support for Medicare reform and health care transformation

    Tochi Iroku-Malize, MD, MPH, MBA, Sterling N. Ransone, Jr., MD, and Steven P. Furr, MD
  • Most Popular

  • Past Week

    • The power of coaching for physicians: transforming thoughts, changing lives

      Kim Downey, PT | Conditions
    • The hidden factor in physician burnout: How the climate crisis is contributing to the erosion of well-being

      Elizabeth Cerceo, MD | Physician
    • Why affirmative action is crucial for health equity and social justice in medicine

      Katrina Gipson, MD, MPH | Policy
    • Unlocking the secrets of cancer conferences: an end-of-life counselor’s journey among pharmaceutical giants

      Althea Halchuck, EJD | Conditions
    • Why doctors aren’t to blame for the U.S. opioid crisis [PODCAST]

      The Podcast by KevinMD | Podcast
    • Nose-brain connection: The surprising link between allergies and mental health revealed

      Kara Wada, MD | Conditions
  • Past 6 Months

    • It’s time to replace the 0 to 10 pain intensity scale with a better measure

      Mark Sullivan, MD and Jane Ballantyne, MD | Conditions
    • “Is your surgeon really skilled? The hidden threat to public safety in medicine.

      Gene Uzawa Dorio, MD | Physician
    • Breaking point: the 5 reasons American doctors are dreaming of walking away from medicine

      Amol Shrikhande, MD | Physician
    • Revolutionize your practice: the value-based care model that reduces physician burnout

      Chandravadan Patel, MD | Physician
    • Unveiling the hidden damage: the secretive world of medical boards

      Alan Lindemann, MD | Physician
    • Breaking the cycle of racism in health care: a call for anti-racist action

      Tomi Mitchell, MD | Policy
  • Recent Posts

    • Why allowing yourself to embrace discomfort is necessary for personal growth

      Jillian Rigert, MD, DMD | Physician
    • Unconventional health care, flawed studies, and biases: Navigating the complexities for optimal well-being

      Kara Wada, MD | Physician
    • Urgent innovation needed to address growing mental health crisis among children and families

      Monika Roots, MD | Conditions
    • The importance of listening in health care: a mother’s journey advocating for children with chronic Lyme disease

      Cheryl Lazarus | Conditions
    • Medical errors and the power of apologies [PODCAST]

      The Podcast by KevinMD | Podcast
    • Finding your ideal work-life balance: tips for prioritizing personal life and achieving professional success

      Zahid Awan, MD | Physician

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 3 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

CME Spotlights

From MedPage Today

Latest News

  • FDA Warns on Certain Forms of Compounded Semaglutide
  • Fired COVID Whistleblower Doesn't Want to Settle His Case
  • Video of ACOG Presenter Being Slapped Goes Viral
  • Bed Bug Anaphylaxis; Heart Block Relationships; What's It Like to Date a Nurse?
  • TAR-200 Led to High Complete Response Rates in BCG-Unresponsive Bladder Cancer

Meeting Coverage

  • TAR-200 Led to High Complete Response Rates in BCG-Unresponsive Bladder Cancer
  • More Success for CAR T-Cell Therapy in Rheumatic Disease
  • Trial Shows RA Can Be Stopped at Preclinical Stage
  • Tenapanor Improves Abdominal Symptoms in Patients With IBS-C
  • Benefits Found for Hand OA Drug Treatments
  • Most Popular

  • Past Week

    • The power of coaching for physicians: transforming thoughts, changing lives

      Kim Downey, PT | Conditions
    • The hidden factor in physician burnout: How the climate crisis is contributing to the erosion of well-being

      Elizabeth Cerceo, MD | Physician
    • Why affirmative action is crucial for health equity and social justice in medicine

      Katrina Gipson, MD, MPH | Policy
    • Unlocking the secrets of cancer conferences: an end-of-life counselor’s journey among pharmaceutical giants

      Althea Halchuck, EJD | Conditions
    • Why doctors aren’t to blame for the U.S. opioid crisis [PODCAST]

      The Podcast by KevinMD | Podcast
    • Nose-brain connection: The surprising link between allergies and mental health revealed

      Kara Wada, MD | Conditions
  • Past 6 Months

    • It’s time to replace the 0 to 10 pain intensity scale with a better measure

      Mark Sullivan, MD and Jane Ballantyne, MD | Conditions
    • “Is your surgeon really skilled? The hidden threat to public safety in medicine.

      Gene Uzawa Dorio, MD | Physician
    • Breaking point: the 5 reasons American doctors are dreaming of walking away from medicine

      Amol Shrikhande, MD | Physician
    • Revolutionize your practice: the value-based care model that reduces physician burnout

      Chandravadan Patel, MD | Physician
    • Unveiling the hidden damage: the secretive world of medical boards

      Alan Lindemann, MD | Physician
    • Breaking the cycle of racism in health care: a call for anti-racist action

      Tomi Mitchell, MD | Policy
  • Recent Posts

    • Why allowing yourself to embrace discomfort is necessary for personal growth

      Jillian Rigert, MD, DMD | Physician
    • Unconventional health care, flawed studies, and biases: Navigating the complexities for optimal well-being

      Kara Wada, MD | Physician
    • Urgent innovation needed to address growing mental health crisis among children and families

      Monika Roots, MD | Conditions
    • The importance of listening in health care: a mother’s journey advocating for children with chronic Lyme disease

      Cheryl Lazarus | Conditions
    • Medical errors and the power of apologies [PODCAST]

      The Podcast by KevinMD | Podcast
    • Finding your ideal work-life balance: tips for prioritizing personal life and achieving professional success

      Zahid Awan, MD | Physician

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Negotiating lower drug prices in America: The tradeoffs are worth it.
3 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...